Immunoassay and clinical chemistry are the two largest segments of the IVD market, collectively accounting for approximately 50% of global IVD revenues. Immunoassay holds the largest technology share at approximately 35% of the total IVD market in 2025. Reagents and kits hold the largest product share at approximately 69% of the market. The consolidation of immunoassay and clinical chemistry analyzers onto integrated core laboratory platforms — combining both disciplines on a single automation track — is the dominant competitive dynamic, with Roche's cobas series, Abbott's Alinity, Siemens Healthineers' Atellica, and Beckman Coulter's DxC competing for high-volume laboratory placements. Menu breadth, turnaround time, and reagent rental financing terms are the primary competitive battlegrounds.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Immunoassay and Clinical Chemistry Market Size and Forecast 2025-2030 by Segment
• Core Laboratory Consolidation — Integrated Platforms and Total Lab Automation
• Immunoassay Technologies — Chemiluminescence, ELISA, CLIA, and Fluorescence
• High-Sensitivity Assays — Troponin, Procalcitonin, and High-Sensitivity CRP
• Clinical Chemistry Menu — Metabolic, Hepatic, Renal, and Therapeutic Drug Monitoring
• Reagent Rental and Placement Financing — Market Size and Business Model Analysis
• Menu Expansion Strategies — New Analytes, Specialty Testing, and Automation Integration
• Competitive Landscape — Roche, Abbott, Siemens Healthineers, Beckman Coulter, and DiaSorin
• Investment and Partnership Opportunities